Alnylam inks $331m drug deal with Roche
Accord affirms value of genetic technique discovered at UMass
In the latest endorsement of a science technique discovered at the University of Massachusetts, the international drug giant Roche signed a $331 million deal with Alnylam Pharmaceuticals Inc. of Cambridge for the rights to develop drugs using RNA interference. (Full article: 679 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
